1999
Open trial of flutamide for treatment of obsessive-compulsive disorder.
Altemus M, Greenberg B, Keuler D, Jacobson K, Murphy D. Open trial of flutamide for treatment of obsessive-compulsive disorder. The Journal Of Clinical Psychiatry 1999, 60: 442-5. PMID: 10453797, DOI: 10.4088/jcp.v60n0704.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderAndrogen receptorEstrogen receptorClassical intracellular androgen receptorsOCD symptomsPrimary outcome measureFuture treatment trialsIntracellular androgen receptorHamilton Rating ScaleGonadal steroid hormonesAndrogen receptor antagonistYale-Brown Obsessive Compulsive ScaleEffect of treatmentBeck Anxiety InventoryLack of responseObsessive Compulsive ScaleOpen trialTreatment trialsReceptor antagonistGonadal steroidsOutcome measuresCompetitive antagonistEstrogen activityFlutamideSteroid hormonesLeptin, neuropeptide Y, and peptide YY in long-term recovered eating disorder patients
Gendall K, Kaye W, Altemus M, McConaha C, La Via M. Leptin, neuropeptide Y, and peptide YY in long-term recovered eating disorder patients. Biological Psychiatry 1999, 46: 292-299. PMID: 10418705, DOI: 10.1016/s0006-3223(98)00292-3.Peer-Reviewed Original ResearchMeSH KeywordsAdipose TissueAdultAnorexia NervosaBody ImageBody Mass IndexBulimiaConvalescenceFemaleHumansNeuropeptide YPeptide YYProteinsSeverity of Illness IndexSpinal Puncture
1993
CSF somatostatin in obsessive-compulsive disorder
Altemus M, Pigott T, L'Heureux F, Davis C, Rubinow D, Murphy D, Gold P. CSF somatostatin in obsessive-compulsive disorder. American Journal Of Psychiatry 1993, 150: 460-464. PMID: 8094599, DOI: 10.1176/ajp.150.3.460.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderCSF somatostatinDrug-free outpatientsSerotonin reuptake inhibitorsSpectrum of disordersSubstantial cognitive deficitsMeasurement of somatostatinPredominant symptomReuptake inhibitorsSomatostatin activitySomatostatin levelsBrain contentPatient subgroupsClinical symptomatologyNormal subjectsNormal volunteersSomatostatinPatientsNeuropharmacological agentsExperimental animalsCognitive deficitsCentral administrationDisordersFunctional significance